Detection of Amyloid Plaques Targeted by Bifunctional USPIO in Alzheimer's Disease Transgenic Mice Using Magnetic Resonance Microimaging

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Wadghiri, Youssef Zaim ^a   Li, Jialin ^d   Wang, Jinhuan ^d   Hoang, Dung Minh ^a   Sun, Yanjie ^a   Xu, Hong ^c   Tsui, Wai ^a   Li, Yongsheng ^a   Boutajangout, Allal ^a   Wang, Andrew ^c   de Leon, Mony ^a,b   Wisniewski, Thomas ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c OCEAN NANOTECH LLC   (United States)

^d TIANJIN HUANHU HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; MACROGOL; MANNITOL; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; EX VIVO STUDY; HISTOLOGY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGE PROCESSING; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; QUANTITATIVE ANALYSIS; VOXEL BASED MORPHOMETRY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MICE; MICE, TRANSGENIC; PLAQUE, AMYLOID;

EID: 84874516217     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057097     Document Type: Article

References (53)

1. Perl DP, (2010) Neuropathology of Alzheimer's disease. Mt Sinai J Med 77: 32-42.
2. Alzheimer's Association website. 2012 Alzheimer's disease facts and figures. Available: http://www.alz.org/downloads/facts_figures_2012.pdf. Accessed 2013 Feb 1.
3. Koffie RM, Farrar CT, Saidi LJ, William CM, Hyman BT, et al. (2011) Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proc Natl Acad Sci U S A 108(46): 18837-18842.
4. Chamberlain R, Wengenack TM, Poduslo JF, Garwood M, Jack CR Jr, (2011) Magnetic resonance imaging of amyloid plaques in transgenic mouse models of Alzheimer's disease. Curr Med Imaging Rev 7: 3-7.
5. Baltes C, Princz-Kranz F, Rudin M, Mueggler T, (2011) Detecting amyloid-beta plaques in Alzheimer's disease. Methods Mol Biol 711: 511-533.
6. Matsuda H, Imabayashi E, (2012) Molecular neuroimaging in Alzheimer's disease. Neuroimaging Clin N Am 22: 57-65.
7. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319.
8. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, et al. (2007) Imaging beta-amyloid burden in aging and dementia. Neurol 68: 1718-1725.
9. Brody DL, Holtzman DM, (2008) Active and passive immunotherapy for neurodegenerative diseass. Annu Rev Neurosci 31: 175-193.
10. Wisniewski T, Konietzko U, (2008) Amyloid-β immunization for Alzheimer's disease. Lancet Neurol 7: 805-811.
11. Wisniewski T, Boutajangout A, (2010) Vaccination as a therapeutic approach for Alzheimer's disease. Mount Sinai Journal of Medicine 77: 17-31.
12. Wisniewski T, Sigurdsson EM, (2010) Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim Biophys Acta Mol Basis Dis 1802: 847-859.
13. Wadghiri YZ, Sigurdsson EM, Sadowski M, Elliot JI, Li Q, et al. (2003) Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance micro-imaging. Magn Reson Med50: 293-302.
14. Sigurdsson EM, Wadghiri YZ, Li Q, Tang CY, Aguilanldo JG, et al. (2002) In vivo detection of Alzheimer's amyloid by magnetic resonance imaging. Neurobiol Aging A1307.
15. Zaim Wadghiri Y, Sigurdsson EM, Sadowski M, Tang CY, Aguilanldo JG, et al. (2003) Detection of Alzheimer's amyloid lesions in transgenic mice by magnetic resonance imaging. Magn Reson Med50: 293-302.
16. Sigurdsson EM, Wadghiri YZ, Sadowski M, Elliot JI, Li Y, et al. (2004) In vivo magnetic resonance of amyloid plaques in Alzheimer's disease model mice. In: Hyman B, editors. The Living Brain and Alzheimer's disease. Berlin: Springer-Verlag.
17. Wadghiri YZ, Sigurdsson EM, Wisniewski T, Turnbull D (2005) MR Imaging of amyloid plaques in transgenic mice. In: Sigurdsson EM, editors. Amyloid Proteins: Methods and Protocols. Totowa, NJ: Humana Press Inc. pp. 365-379.
18. Sigurdsson EM, Wadghiri YZ, Mosconi L, Blind JA, Knudsen E, et al. (2008) A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol Aging 29: 836-877.
19. Wadghiri YZ, Hoang DM, Wisniewski T, Sigurdsson EM, (2012) In vivo imaging of amyloid plaques in transgenic mice. Methods in Molecular Biology 849: 435-451.
20. Benveniste H, Einstein G, Kim KR, Hulette C, Johnson GA, (1999) Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc Natl Acad Sci (USA) 96: 14079-14084.
21. Poduslo JF, Wengenack TM, Curran GL, Wisniewski T, Sigurdsson EM, et al. (2002) Molecular contrast enhanced magnetic resonance imaging of Alzheimer's amyloid plaques. Neurobiol Dis 11: 315-329.
22. Jack CR, Garwood M, Wengenack TM, Borowski B, Curran GL, et al. (2004) In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn Reson Med52(6): 1263-1271.
23. Braakman N, Matysik J, Van Duinen SG, Verbeek F, Schliebs R, et al. (2006) Longitudinal assessment of Alzheimer's beta-amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging. J Magn Reson Imaging 24(3): 530-536.
24. Jack CR Jr, Wengenack TM, Reyes DA, Garwood M, Curran GL, et al. (2005) In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J Neurosci 25: 10041-10048.
25. Vanhoutte G, Dewachter I, Borghgraef P, Van LF, Van der LA, (2005) Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease. Magn Reson Med53: 607-613.
26. Scholtzova H, Wadghiri YZ, Douadi M, Sigurdsson EM, Li Y, et al. (2008) A NMDA receptor antagonist leads to behavioral improvement and amyloid reduction in Alzheimer's disease model transgenic mice shown by micro-magnetic resonance imaging. J Neurosci Res 86: 2784-2791.
27. Yang J, Zaim Wadghiri Y, Hoang DM, Tsui W, Sun Y, et al. (2011) Detection of amyloid plaques targeted by USPIO-Aβ1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. Neuroimage 55: 1600-1609.
28. McLachlan SJ, Morris MR, Lucas MA, Fisco RA, Eakins MN, et al. (1994) Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging 4: 301-307.
29. Winer JL, Kim PE, Law M, Liu CY, Apuzzo ML, (2011) Visualizing the future: enhancing neuroimaging with nanotechnology. World Neurosurg 75: 626-637.
30. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, et al. (1990) Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 175(2): 489-493.
31. Calvo P, Gouritin B, Chacun H, Desmaele D, D'Angelo J, et al. (2001) Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 18: 1157-1166.
32. Provenzale JM, Silva GA, (2009) Uses of nanoparticles for central nervous system imaging and therapy. AJNR Am J Neuroradiol 30: 1293-1301.
33. Calvo P, Gouritin B, Villarroya H, Eclancher F, Giannavola C, et al. (2002) Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur J Neurosci 15: 1317-1326.
34. Ku S, Yan F, Wang Y, Sun Y, Yang N, et al. (2010) The blood-brain barrier penetration and distribution of PEGylated fluorescein-doped magnetic silica nanoparticles in rat brain. Biochem Biophys Res Commun 394: 871-876.
35. Li J, Feng L, Fan L, Zha Y, Guo L, et al. (2011) Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 32: 4943-4950.
36. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, et al. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Med 4: 97-100.
37. Sigurdsson EM, Scholtzova H, Mehta P, Frangione B, Wisniewski T, (2001) Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am J Pathol 159: 439-447.
38. Maggio JE, Stimson ER, Ghilardi JR, Allen CJ, Dahl CE, et al. (1992) Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide. Proc Natl Acad Sci USA 89: 5462-5466.
39. Pike CJ, Walencewicz AJ, Glabe C, Cotman C, (1991) In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 563: 311-314.
40. Sadowski M, Pankiewicz J, Scholtzova H, Ripellino JA, Li Y, et al. (2004) Blocking the apolipoprotein E/ß-amyloid interaction reduces β-amyloid toxicity and decreases β-amyloid load in transgenic mice. Am J Pathol 165: 937-948.
41. Nieman BJ, Szulc KU, Turnbull DH, (2009) Three-dimensional, in vivo MRI with self-gating and image coregistration in the mouse. Magn Reson Med61: 1148-1157. 10.1002/mrm.21945 [doi].
42. Sadowski M, Pankiewicz J, Scholtzova H, Mehta P, Prelli F, et al. (2006) Blocking the apolipoproteinE/Amyloid β interaction reduces the parenchymal and vascular amyloid-β deposition and prevents memory deficit in AD transgenic mice. Proc Natl Acad Sci (USA) 103(49): 18787-18792.
43. Ramakrishnan M, Kandimalla KK, Wengenack TM, Howell KG, Poduslo JF, (2009) Surface plasmon resonance binding kinetics of Alzheimer's disease amyloid beta peptide-capturing and plaque-binding monoclonal antibodies. Biochem 48: 10405-10415.
44. Sawiak SJ, Wood NI, Williams GB, Morton AJ, Carpenter TA, (2009) Voxel-based morphometry in the R6/2 transgenic mouse reveals differences between genotypes not seen with manual 2D morphometry. Neurobiol Dis 33: 20-27.
45. Ashburner J, (2009) Computational anatomy with the SPM software. Magn Reson Imaging 27: 1163-1174.
46. Dubois A, Herard AS, Flandin G, Duchesnay E, Besret L, et al. (2008) Quantitative validation of voxel-wise statistical analyses of autoradiographic rat brain volumes: application to unilateral visual stimulation. Neuroimage 40: 482-494.
47. Dubois A, Herard AS, Delatour B, Hantraye P, Bonvento G, et al. (2010) Detection by voxel-wise statistical analysis of significant changes in regional cerebral glucose uptake in an APP/PS1 transgenic mouse model of Alzheimer's disease. Neuroimage 51: 586-598.
48. Oude Engberink RD, Blezer EL, Dijkstra CD, van der Pol SM, van der Toorn A, et al. (2010) Dynamics and fate of USPIO in the central nervous system in experimental autoimmune encephalomyelitis. NMR Biomed 23(9): 1087-1096.
49. Yasuhara T, Hara K, Maki M, Xu L, Yu G, et al. (2010) Mannitol facilitates neurotrophic factor up-regulation and behavioural recovery in neonatal hypoxic-ischaemic rats with human umbilical cord blood grafts. J Cell Mol Med 14: 914-921.
50. McCarty DM, Dirosario J, Gulaid K, Muenzer J, Fu H, (2009) Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice. Gene Ther 16: 1340-1352.
51. Larbanoix L, Burtea C, Laurent S, Van LF, Toubeau G, et al. (2010) Potential amyloid plaque-specific peptides for the diagnosis of Alzheimer's disease. Neurobiol Aging 31(10): 1679-1689.
52. Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, et al. (1990) Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 175(2): 494-498.
53. Bharadwaj PR, Dubey AK, Masters CL, Martins RN, Macreadie IG, (2009) Abeta aggregation and possible implications in Alzheimer's disease pathogenesis. J Cell Mol Med 13: 412-421.